Cover Image
市場調查報告書

GW Pharmaceuticals plc:產品平台分析

GW Pharmaceuticals plc - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224709
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
GW Pharmaceuticals plc:產品平台分析 GW Pharmaceuticals plc - Product Pipeline Review - 2015
出版日期: 2015年04月22日 內容資訊: 英文 43 Pages
簡介

GW Pharmaceuticals plc是致力於研究開發及商品化大麻素處方藥及植物性醫藥品的醫藥品公司。

本報告提供GW Pharmaceuticals plc的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

GW Pharmaceuticals plc的基本資料

GW Pharmaceuticals plc概要

  • 主要資訊
  • 企業資料

GW Pharmaceuticals plc:R&D概要

  • 主要的治療範圍

GW Pharmaceuticals plc:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

GW Pharmaceuticals plc:開發中產品概況

  • 後期開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

GW Pharmaceuticals plc:藥物簡介

  • nabiximols
  • GWP-42003
  • GWP-42003-P
  • GWP-42004
  • GWP-42002
  • Epidiolex
  • GWP-42006

GW Pharmaceuticals plc:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

GW Pharmaceuticals plc:最近的開發平台趨勢

GW Pharmaceuticals plc:暫停中的計劃

GW Pharmaceuticals plc:企業發表

GW Pharmaceuticals plc:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06967CDB

Summary

Global Markets Direct's, 'GW Pharmaceuticals plc - Product Pipeline Review - 2015', provides an overview of the GW Pharmaceuticals plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GW Pharmaceuticals plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of GW Pharmaceuticals plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of GW Pharmaceuticals plc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the GW Pharmaceuticals plc's pipeline products

Reasons to buy

  • Evaluate GW Pharmaceuticals plc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of GW Pharmaceuticals plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the GW Pharmaceuticals plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of GW Pharmaceuticals plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of GW Pharmaceuticals plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of GW Pharmaceuticals plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • GW Pharmaceuticals plc Snapshot
    • GW Pharmaceuticals plc Overview
    • Key Information
    • Key Facts
  • GW Pharmaceuticals plc - Research and Development Overview
    • Key Therapeutic Areas
  • GW Pharmaceuticals plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • GW Pharmaceuticals plc - Pipeline Products Glance
    • GW Pharmaceuticals plc - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • GW Pharmaceuticals plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • GW Pharmaceuticals plc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • GW Pharmaceuticals plc - Drug Profiles
    • Epidiolex
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nabiximols
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GWP-42003
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GWP-42004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GWP-42006
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (GWP-42002 + GWP-42003)
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • GW Pharmaceuticals plc - Pipeline Analysis
    • GW Pharmaceuticals plc - Pipeline Products by Target
    • GW Pharmaceuticals plc - Pipeline Products by Route of Administration
    • GW Pharmaceuticals plc - Pipeline Products by Molecule Type
    • GW Pharmaceuticals plc - Pipeline Products by Mechanism of Action
  • GW Pharmaceuticals plc - Recent Pipeline Updates
  • GW Pharmaceuticals plc - Dormant Projects
  • GW Pharmaceuticals plc - Company Statement
  • GW Pharmaceuticals plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • GW Pharmaceuticals plc, Key Information
  • GW Pharmaceuticals plc, Key Facts
  • GW Pharmaceuticals plc - Pipeline by Indication, 2015
  • GW Pharmaceuticals plc - Pipeline by Stage of Development, 2015
  • GW Pharmaceuticals plc - Monotherapy Products in Pipeline, 2015
  • GW Pharmaceuticals plc - Combination Treatment Modalities in Pipeline, 2015
  • GW Pharmaceuticals plc - Phase III, 2015
  • GW Pharmaceuticals plc - Phase II, 2015
  • GW Pharmaceuticals plc - Phase I, 2015
  • GW Pharmaceuticals plc - Preclinical, 2015
  • GW Pharmaceuticals plc - Pipeline by Target, 2015
  • GW Pharmaceuticals plc - Pipeline by Route of Administration, 2015
  • GW Pharmaceuticals plc - Pipeline by Molecule Type, 2015
  • GW Pharmaceuticals plc - Pipeline Products by Mechanism of Action, 2015
  • GW Pharmaceuticals plc - Recent Pipeline Updates, 2015
  • GW Pharmaceuticals plc - Dormant Developmental Projects,2015
  • GW Pharmaceuticals plc, Other Locations
  • GW Pharmaceuticals plc, Subsidiaries

List of Figures

  • GW Pharmaceuticals plc - Pipeline by Top 10 Indication, 2015
  • GW Pharmaceuticals plc - Pipeline by Stage of Development, 2015
  • GW Pharmaceuticals plc - Monotherapy Products in Pipeline, 2015
  • GW Pharmaceuticals plc - Pipeline by Top 10 Target, 2015
  • GW Pharmaceuticals plc - Pipeline by Top 10 Route of Administration, 2015
  • GW Pharmaceuticals plc - Pipeline by Top 10 Molecule Type, 2015
  • GW Pharmaceuticals plc - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top